Literature DB >> 12144820

Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer.

David Butler1, Claire Collins, Mohamed Mabruk, Mary B Leader, Elaine W Kay.   

Abstract

OBJECTIVE: In a previous study using the same cases of squamous cervical neoplasia and microinvasive carcinoma (MICA) we found an association between FHIT gene deletion and infection with high-risk HPV (HR HPV). The purpose of this study was to evaluate Fhit protein expression by immunohistochemistry in order to determine whether FHIT gene deletion or infection with HR HPV correlated with aberrant protein expression and grade of lesion.
METHODS: A total of 74 archival LLETZ biopsy cases consisting of 23 cervical intraepithelial neoplasia grade 1 (CIN1), 28 CIN3, and 23 MICA cases were selected for Fhit immunostaining. The results of this study on Fhit immunostaining were analyzed in relation to our previous findings using Epi-Info and SPSS-PC statistical analysis software.
RESULTS: Fifty percent (14/28) of CIN3 lesions and 78% (18/23) of MICA lesions had a marked reduction or absence of Fhit protein expression (P = <0.001, strength of association, Cramers' V, 0.632). CIN1 lesions were found to have moderate to strong cytoplasmic expression of Fhit. Seventy percent of cases in this study with reduced/absent Fhit protein expression were also positive for FHIT gene loss of heterozygosity (LOH) (P = 0.04, strength of association, phi, 0.254). A significant statistical relationship was found between Fhit protein expression and HPV 16 infection in combined CIN1, CIN3, and MICA cases (P = <0.001). Eighty-seven percent of cases with reduced/absent Fhit protein expression were positive for HPV 16 (strength of association, phi, 0.552). Ninety percent of HPV 16 and 31 positive cases had reduced/absent Fhit expression.
CONCLUSION: Our findings suggest an association between HPV infection and FHIT gene abnormalities raising the possibility of a mechanistic role for the FHIT gene as a cofactor with HPV in triggering the development of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12144820     DOI: 10.1006/gyno.2002.6712

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomas.

Authors:  Naoki Yanagawa; Mitsumasa Osakabe; Masahiro Hayashi; Gen Tamura; Teiichi Motoyama
Journal:  Virchows Arch       Date:  2008-02-26       Impact factor: 4.064

2.  Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation.

Authors:  Roberto Cirombella; Giuseppe Montrone; Antonella Stoppacciaro; Simona Giglio; Stefano Volinia; Paolo Graziano; Kay Huebner; Andrea Vecchione
Journal:  Cancer Lett       Date:  2010-05-28       Impact factor: 8.679

Review 3.  The FHIT gene product: tumor suppressor and genome "caretaker".

Authors:  Catherine E Waters; Joshua C Saldivar; Seyed Ali Hosseini; Kay Huebner
Journal:  Cell Mol Life Sci       Date:  2014-10-05       Impact factor: 9.261

4.  Molecular and epigenetic analysis of the fragile histidine triad tumour suppressor gene in equine sarcoids.

Authors:  Maria Strazzullo; Annunziata Corteggio; Gennaro Altamura; Romina Francioso; Franco Roperto; Maurizio D'Esposito; Giuseppe Borzacchiello
Journal:  BMC Vet Res       Date:  2012-03-16       Impact factor: 2.741

5.  Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma.

Authors:  Alfredo Hidalgo; Michael Baudis; Iver Petersen; Hugo Arreola; Patricia Piña; Guelaguetza Vázquez-Ortiz; Dulce Hernández; José González; Minerva Lazos; Ricardo López; Carlos Pérez; José García; Karla Vázquez; Brenda Alatorre; Mauricio Salcedo
Journal:  BMC Cancer       Date:  2005-07-09       Impact factor: 4.430

6.  A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions.

Authors:  Jack Y Yang; Mary Qu Yang; Zuojie Luo; Yan Ma; Jianling Li; Youping Deng; Xudong Huang
Journal:  BMC Genomics       Date:  2008       Impact factor: 3.969

7.  Cancer and the FRA3B/FHIT fragile locus: it's a HIT.

Authors:  K Huebner; C M Croce
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.